

# Medicinal Cannabis and Chronic Pain Project

## Science-Based Education in Times of Legalization



### References for Module 1

<http://adai.uw.edu/mcacp>

Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. *Clin Pharmacol Ther* 2011;90(6):844-851. View abstract: <http://dx.doi.org/10.1038/clpt.2011.188>

Abrams DI, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology* 2007;68(7):515-521. View abstract: <http://dx.doi.org/10.1212/01.wnl.0000253187.66183.9c>

Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. *Clin Pharmacol Ther* 2007;82(5):572-578. View abstract: <http://dx.doi.org/10.1038/sj.clpt.6100200>

Aggarwal SK, Carter GT, Sullivan MD, Zumbrennen C, Morrill R, Mayer JD. Characteristics of patients with chronic pain accessing treatment with medicinal cannabis in Washington State. *J Opioid Manag* 2009;5(2):257-286. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/19947069>

Aggarwal SK, Carter GT, Sullivan MD, Zumbrennen C, Morrill R, Mayer JD. Prospectively surveying health-related quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington State reveals managed chronic illness and debility. *Am J Hosp Palliat Care* 2013;30(6):523-531. View abstract: <http://dx.doi.org/10.1177/1049909112454215>

Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. *Clin J Pain* 2013;29(2):162-171. View abstract: <http://dx.doi.org/10.1097/AJP.0b013e31824c5e4c>

Aragona M, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. *Clin Neuropharmacol* 2009;32(1):41-7. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/18978501>

Attal N, et al. Are oral cannabinoids safe and effective in refractory neuropathic pain? *Eur J Pain* 2004;8:173-7. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/14987627>

Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. *JAMA Intern Med* 2014;174(10):1668-73. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/25154332>

Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. *J Ethnopharmacol* 2006;105(1-2):1-25. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/16540272>

Bhattacharyya S, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. *Neuropsychopharmacology* 2010;35(3):764-74. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055598>

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology* 2006;45(1):50-52. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/16282192>

Boehnke KR, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. *J Pain* 2016;17(6):739-44. View abstract: <https://www.ncbi.nlm.nih.gov/pubmed/27001005>

Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. *Mayo Clin Proc*. 2012;87(2):172-186. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538401>

Brenneisen R. Chemistry and analysis of phytocannabinoids and other Cannabis constituents. In: Elsohly M (ed.). Marijuana and the Cannabinoids. Totowa, NY: Humana Press, pp. 17-49, 2007. Free online: <http://www.medicinalgenomics.com/wp-content/uploads/2011/12/Chemical-constituents-of-cannabis.pdf>

Carlini EA, Karniol IG, Renault PF, Schuster CR. Effects of marijuana in laboratory animals and man. *Brit J Pharmacol* 1974;50:299-309

Carlini EA, Leite JR, Tannhauser M, Berardi AC. Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. *J Pharm Pharmacol* 1973;25: 664-665. View abstract: <http://onlinelibrary.wiley.com/doi/10.1111/j.2042-7158.1973.tb10660.x/abstract>

Carlini EA, Mechoulam R, Lander N. Anticonvulsant activity of four oxygenated cannabidiol derivatives. *Res Comm Chem Path Pharmacol* 1975;12: 1-16. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/1188178>

Carter GT, Weydt P, Kyashna-Tocha M, Abrams DI. Medicinal cannabis: rational guidelines for dosing. *IDrugs* 2004;7(5):464-470. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/15154108>

Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses -- a US epidemic. *MMWR Morb Mortal Wkly Rep* 2012;13;61(1):10-13. Free online: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm>

Clermont-Gnamien S, et al. Utilisation thérapeutique du delta-9-tétrahydrocannabinol (dronabinol) dans les douleurs neuropathiques réfractaires. *Presse Med* 2002;31(39 Pt1):1840-5.

Collin C, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. *Neurol Res* 2010;32(5):451-9. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/20307378>

Desroches J, Beaulieu P. Opioids and cannabinoids interactions: involvement in pain management. *Curr Drug Targets* 2010;11(4):462-473. <http://www.ncbi.nlm.nih.gov/pubmed/20017728>

De Petrocellis L, Di Marzo V. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. *J Neuroimmune Pharmacol* 2010;5: 103-121. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/19847654>

De Petrocellis L, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol* 2011;163(7):1479-94. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165957/>

Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. *JAMA* 2016;315(15):1642-1645. Free online: <http://jamanetwork.com/journals/jama/fullarticle/2503508>

Ellis RJ, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. *Neuropsychopharmacology* 2009;34(3):672-680. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3066045>

Englund A, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. *J Psychopharmacol* 2013;27(1):19-27. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/23042808>

Evans FJ. Cannabinoids: the separation of central from peripheral effects on a structural basis. *Planta Med* 1991;57: S60-S67. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/1659702>

Fairbairn JW, Pickens JT. Activity of cannabis in relation to its delta1-trans-tetrahydro-cannabinol content. *British J Pharmacol* 1981;72:401-9. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2071597>

Frank B, Serpell MG, Hughes J. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomized, crossover, double blind study. *BMJ* 2008 26;336(7637):199-201. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213874>

Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. *J*

Am Chem Soc 1964;86:1646-7. View abstract: <http://pubs.acs.org/doi/abs/10.1021/ja01062a046>

Grant I, Atkinson JH, Gouaux B, Wilsey B. Medical marijuana: clearing away the smoke. *Open Neurol J*. 2012;6:18-25. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358713/>  
Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005-2009. *Cannabinoids*. 2010;5(special issue):1-21. Free online: <http://cannabis-med.org/index.php?tpl=cannabinoids&id=243&lng=en&red=cannabinoidslist>

Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. *Neuropharmacology* 2004; 47(Suppl 1):345-58. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/15464149>

Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci* 2009;30: 515-527. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/19729208>

Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. *J Pain Symptom Manage* 2010;39(2):167-79. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/19896326>

Joy JE, Watson SJ Jr, Benson JA. *Marijuana and Medicine: Assessing the Science Base*. Washington, D.C.: The National Academy Press, 1999. Free online: <https://www.nap.edu/catalog/6376/marijuana-and-medicine-assessing-the-science-base>

Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. *JAMA* 2003;290(13):1757-1762. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/14519710>

Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. *Int Rev Psychiatry* 2009;21(2):163-171. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/19367510>

Leite JR, Carlini EA, Lander N, Mechoulam R. Anticonvulsant effects of the (-) and (+) isomers of Cannabidiol and their Dimethylheptyl homologs. *Pharmacology* 1982;24: 141-146. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/7071126>

Le Strat Y, Le Foll B. Obesity and cannabis use: results from 2 representative national surveys. *Am J Epidemiol* 2011;174(8):929-933. Free online: <http://aje.oxfordjournals.org/content/174/8/929.long>

Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *Brit J Clin Pharmacol* 2011;72(5):735-744. Free online: <http://dx.doi.org/10.1111/j.1365-2125.2011.03970.x>

Lynch ME, Clark AJ. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. *J Pain Symptom Manage* 2003;25(6):496-498. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/12782429>

Mackie K. Cannabinoid receptors as therapeutic targets. *Annu Rev Pharmacol Toxicol* 2006;46:101-22. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/16402900>

McPartland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? Co-published simultaneously in *Journal of Cannabis Therapeutics* 2001;1(3/4)103-132; and: *Cannabis Therapeutics in HIV/AIDS* (ed: Ethan Russo) Haworth Integrative Healing Press, pp. 103-132, 2001.

Mechoulam R. Cannabis – a valuable drug that deserves better treatment. *Mayo Clin Proc*. 2012 February; 87(2): 107-109. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498425/>

Mehmedic Z, et al. Potency trends of delta(9)-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. *J Forensic Sci* 2010;55: 1209-1217. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/20487147>

Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. *Circulation* 2001;103(23):2805-2809. Free online: <http://circ.ahajournals.org/content/103/23/2805.long>

Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic

review of randomized trials of oral opioids. *Arthritis Research & Therapy* 2005;7:R1046-R1051. Free online: <http://arthritis-research.com/content/7/5/R1046>

Morgan, CJA, Schafer, G, Freeman, TP, Curran, HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. *Br J Psychiatry* 2010;197(4):285-290. Free online: <http://bjp.rcpsych.org/content/197/4/285.long>

National Academies of Sciences, Engineering, and Medicine. *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: The National Academy Press, 2017. Free online: <https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state>

Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). *Mult Scler* 2012;18(2):219-228. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/21878454>

Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. *Pain* 2007;133(1-3):210-220. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/17997224>

Pacey AA, et al UK. Modifiable and non-modifiable risk factors for poor sperm morphology. *Hum Reprod* 2014;29(8):1629-1636. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/24899128>

Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. *Am J Med* 2013;126(7):583-589. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/23684393>

Pertwee RG, et al. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. *Br J Pharmacol* 2007;150:586-594. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189766/>

Piomelli D, Russo EB. The Cannabis sativa versus Cannabis indica debate: An interview with Ethan Russo, MD. *Cannabis and Cannabinoid Research* 2016;1(1):44-46. Free online: <http://online.liebertpub.com/doi/pdfplus/10.1089/can.2015.29003.ebr>

Portenoy RK, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. *J Pain* 2012;13(5):438-49. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/22483680>

Robson P. Abuse potential and psychoactive effects of  $\delta$ -9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. *Expert Opin Drug Saf* 2011;10(5):675-685. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/21542664>

Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology* 2005 ;65(6):812-819. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/16186518>

Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. *Clin Ther* 2007;29(9):2068-2079. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/18035205>

Romano LL, Hazekamp A. Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine. *Cannabinoids* 2013;1(1):1-11. Free online: <http://www.cannabis-med.org/index.php?tpl=cannabinoids&id=276&lng=en>

Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol* 2011;163(7):1344-64. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/>

Russo EB, Hohmann AG. Role of cannabinoids in pain management. In: *Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches* 2013, 181-197. View abstract: [http://link.springer.com/chapter/10.1007%2F978-1-4614-1560-2\\_18](http://link.springer.com/chapter/10.1007%2F978-1-4614-1560-2_18)

Russo EB. Cannabinoids in the management of difficult to treat pain. *Ther Clin Risk Manag* 2008;4(1):245-259. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/>

Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. *J Pain* 2008;9(2):164-173. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/17974490>

Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. *Clin Pharmacol Ther* 1978;23(4):397-401. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/343969>

Sumpton JE, Moulin DE. Fibromyalgia. *Handb Clin Neurol* 2014;119:513-27. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/24365316>

Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. *BMJ* 2004;329(7460):253. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC498019/>

Svendsen KB, Jensen TS, Bach FW. Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis—secondary publication. *Ugeskr Laeger* 2005;167(25-31):2772–2774. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/16014264>

Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. *N Engl J Med* 2014;370(23):2219-2227. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/24897085>

Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. *Mult Scler* 2006;12(5):639-645. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/17086911>

Wallace M, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. *Anesthesiology* 2007;107(5):785-796. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/18073554>

Wang T, Collet J, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systemic review. *CMAJ* 2008;178(13):1669-78. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413308/>

Ware MA, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ* 2010;182(14):E694-E701. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950205/>

Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. *Anesth Analg* 2010;110(2):604-10. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/20007734>

Watson SJ, Benson JA, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. *Arch Gen Psychiatry* 2000;57(6):547-555. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/10839332>

Wilsey B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J Pain* 2008;9(6):506-521. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/18403272>

Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. *Science* 2002;296(5568):678-82. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/11976437>

Wissel J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. *J Neurol* 2006;253(10):1337-1341. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/16988792>

Zajicek J, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. *Lancet* 2003;362(9395):1517-1526. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/14615106>

**Take the MCaCP trainings online at**  
<http://adai.uw.edu/mcacp>